
ImpriMed will be exhibiting at ASH to showcase our AI-driven precision medicine platform for hematologic malignancies. Visit our booth #226 to learn how our ex vivo drug sensitivity testing and predictive analytics generate patient-specific insights to help guide treatment decisions.
Developing a small molecule, antibody, antibody conjugate, or degrader for hematologic malignancies?
Bring us your development questions:
xCellSense® helps answer them with functional data from fresh primary patient cells, before or alongside your clinical program.
Building AI models for drug discovery? Your models need functional response data from patient cells, not just cell lines. We generate it, paired with available molecular profiles.
Book a meeting with us: https://cal.com/imprimed-cro/ash2026?month=2026-12&overlayCalendar=true&duration=30